Avadel Pharmaceuticals' (AVDL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Avadel Pharmaceuticals (NASDAQ:AVDL - Free Report) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $21.00 target price on the stock. HC Wainwright also issued estimates for Avadel Pharmaceuticals' Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $1.44 EPS, FY2028 earnings at $1.54 EPS and FY2029 earnings at $1.83 EPS.

A number of other analysts have also recently commented on the company. UBS Group reduced their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, January 13th. Piper Sandler reduced their target price on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating for the company in a report on Friday, January 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "buy" rating and a $12.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Avadel Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $19.88.

Remove Ads

Avadel Pharmaceuticals Trading Up 0.4 %

NASDAQ AVDL traded up $0.03 during trading hours on Tuesday, hitting $7.91. 731,675 shares of the company's stock traded hands, compared to its average volume of 1,185,134. Avadel Pharmaceuticals has a 52 week low of $7.39 and a 52 week high of $19.09. The firm has a market capitalization of $762.22 million, a P/E ratio of -10.01 and a beta of 1.28. The business's fifty day moving average price is $8.62 and its two-hundred day moving average price is $11.43.

Insider Buying and Selling at Avadel Pharmaceuticals

In related news, Director Peter J. Thornton purchased 10,000 shares of the firm's stock in a transaction on Monday, January 13th. The shares were acquired at an average price of $8.04 per share, for a total transaction of $80,400.00. Following the purchase, the director now directly owns 104,055 shares in the company, valued at $836,602.20. This trade represents a 10.63 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Thomas S. Mchugh acquired 5,000 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $10.49 per share, with a total value of $52,450.00. Following the acquisition, the chief financial officer now directly owns 85,500 shares in the company, valued at approximately $896,895. The trade was a 6.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 42,981 shares of company stock valued at $400,005 in the last three months. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Large investors have recently made changes to their positions in the company. PVG Asset Management Corp purchased a new position in Avadel Pharmaceuticals during the 4th quarter valued at approximately $358,000. Two Seas Capital LP boosted its position in shares of Avadel Pharmaceuticals by 90.6% during the 4th quarter. Two Seas Capital LP now owns 4,296,449 shares of the company's stock valued at $45,156,000 after acquiring an additional 2,042,669 shares during the last quarter. Zimmer Partners LP purchased a new position in shares of Avadel Pharmaceuticals in the fourth quarter valued at $420,000. Tang Capital Management LLC grew its holdings in shares of Avadel Pharmaceuticals by 21.7% in the fourth quarter. Tang Capital Management LLC now owns 1,497,500 shares of the company's stock valued at $15,739,000 after purchasing an additional 267,500 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in Avadel Pharmaceuticals by 32.1% in the fourth quarter. ProShare Advisors LLC now owns 30,592 shares of the company's stock worth $322,000 after purchasing an additional 7,433 shares during the last quarter. 69.19% of the stock is owned by institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.